MedTrace Logo

Comparison of Two Drugs Bupivacaine and Ropivacaine for Postoperative Analgesia in Bilateral Superficial Cervical Plexus Block After Thyroidectomy

NCT07779551 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-08-21

No results posted yet for this study

Summary

There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block.

Conditions

  • Postoperative Pain

Interventions

PROCEDURE

Group 1 will receive 10ml of 0.25% bupivacaine

After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure.

PROCEDURE

Group 2 will receive 10ml of 0.25% ropivacaine on each side.

After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure

Sponsors & Collaborators

  • Sargodha Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-22
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07779551 on ClinicalTrials.gov